This study added curcumin to the chemo drug docetaxel in men and postmenopausal women with advanced or metastatic breast cancer. Of the fourteen people in the study, the authors say that most of them experienced some improvement. . . .  Seven had their tumour markers decrease and four had them decrease up to 50%. There was no progression of the disease in any of them, and there was an antiangiogenic effect, reducing the growth of the new blood vessels the tumour produces to feed itself.

Though this study was primarily designed to test the safety of adding curcumin and not as an efficacy study, the authors call the efficacy results encouraging.

  • Cancer Biol Ther 2010;9:1-7
This Barrie website created by Piggybank Marketing